JAMPRO
30.9.2021 21:32:09 CEST | Business Wire | Press release
The Jamaica Promotions Corporation (JAMPRO) will be staging Explore: Do Business Jamaica Virtual Investment Conference (DBJVIC) from November 17 – 18, 2021 to introduce local and international investors to business opportunities in the island’s growing industries.
The event will showcase emerging projects and new developments in Agribusiness, Outsourcing, Manufacturing, Energy, Tourism, and the Creative Industries through over 30 panels, interviews and discussions with government and business leaders. The investment conference aims to foster business and stakeholder relationships and will shed light on Jamaica’s COVID-19 economic recovery efforts.
The conference will be staged concurrently via two platforms; one is a virtual interactive business event portal that will facilitate a real-time engagement experience and B2B meetings, the second is a live stream event via social media that will accommodate and drive increased awareness of Jamaica’s economic progress. This format will help JAMPRO to engage attendees including current and potential investors, JAMPRO clients, private and public sector stakeholders, and diplomatic missions.
JAMPRO anticipates extensive global participation based on the planned international promotions which will ensure the leveraging of the virtual B2B meeting platform by potential investors.
New opportunity to do business
Speaking on the event, Jamaica’s Minister of Industry, Investment, and Commerce, The Honourable Audley Shaw, CD, MP., noted that the virtual investment conference has presented a new opportunity for the government to amplify the promotion of Jamaica’s business opportunities.
He explained, “This virtual conference will allow us to reach and directly engage investors across the globe who are interested in doing business with Jamaica but need further market intelligence and guidance on the potential that is available in the island’s sectors. From our perspective, it is the right time to host this global event, as persons are seeking new ventures as the world slowly returns to normality .”
Diane Edwards, President of JAMPRO, echoed the Minister’s statements, and expressed confidence in the conference’s ability to deliver results for Jamaica and attendees, she said, “The format of the conference is powerful, because it presents an excellent opportunity for global business leaders to get valuable insight on Jamaican investment opportunities, engage their colleagues in various industries, and explore bankable projects, all in the location of their choice. We believe that this conference will lead to the development of lucrative partnerships and financial opportunities for local and international investors. ”
Persons can register for the event at explore.dobusinessjamaica.com
ABOUT THE EXPLORE: DO BUSINESS JAMAICA VIRTUAL INVESTMENT CONFERENCE (DBJVIC)
Explore: Do Business Jamaica Virtual Investment Conference is a 2-day event that will highlight investment and other business opportunities in Jamaica. The event, hosted by Jamaica’s investment and export promotion agency, JAMPRO, will provide a platform for attendees to learn more about Jamaican investment opportunities, see lucrative projects, and build business relationships.
Explore Do Business Jamaica Virtual Investment Conference is sponsored by the Foundations for Competitiveness and Growth Project (FCGP), National Commercial Bank (NCB), Mystique Integrated, and M-One Productions
For more information on the conference, please visit https://explore.dobusinessjamaica.com/ .
Follow JAMPRO on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005861/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom